Triple Incretin Deal Benchmarks in Metabolic & Obesity

Median Upfront

$1.2B

Range: $631M - $1.7B

Total Deal Value

$5.6B

Range: $3.7B - $7.6B

Royalty Rate

17.2% - 30%

Tiered up to 35%

Dev Milestones

$803M

Range: $544M - $1.1B

Model Your Deal

Market Analysis

Triple Incretin therapies in metabolic & obesity have seen significant M&A and licensing activity in recent years. Based on analysis of 1,400+ verified transactions, the median upfront payment for a Phase 2 triple incretin asset in metabolic & obesity is $1.2B, with total deal values reaching $5.6B. Development milestones average $803M, while regulatory milestones contribute $981M.

The metabolic & obesity triple incretin landscape is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for triple incretin metabolic & obesity deals range from 17.2% to 30% at the base tier, with tiered escalation reaching 21.2%-35% on blockbuster sales. Commercial milestones averaging $2.7B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a triple incretin metabolic & obesity licensing deal?

Based on our analysis, Phase 2 triple incretin licensing deals in metabolic & obesity average $1.2B in upfront payments, with a range of $631M to $1.7B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for triple incretin metabolic & obesity transactions?

The median total deal value for Phase 2 triple incretin assets in metabolic & obesity is $5.6B, ranging from $3.7B to $7.6B. This includes development milestones ($803M), regulatory milestones ($981M), and commercial milestones ($2.7B).

What royalty rates are standard for triple incretin deals in metabolic & obesity?

Base royalty rates for triple incretin metabolic & obesity transactions range from 17.2% to 30%, with tiered escalations reaching 21.2%-35% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in triple incretin metabolic & obesity deals?

Triple Incretin metabolic & obesity deals allocate approximately 79% of total deal value to milestones. Development milestones ($803M) make up the largest share, followed by commercial milestones ($2.7B) and regulatory milestones ($981M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Metabolic & Obesity

View

GLP-1 Agonist in Metabolic & Obesity

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need a decision for one asset?

The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.

Configure Brief — $2,500About 30 data-backed pages · Invoiced at intake · 30-minute walkthrough